Safely Guiding the Immune System to Fight Disease
Eradivir Makes Small Molecules That Target Diseased Cells and Viruses Flagging Them for Clearance by the Immune System
Our Vision
With a toolkit of these antibody recruiting small molecules, we are advancing a pipeline of candidates to treat multiple diseases, from viral infections to cancer.
Rethinking Influenza
According to the World Health Organization, seasonal influenza causes an estimated one billion infections annually, including three to five million cases of severe illness and up to 650,000 respiratory deaths worldwide.
While antiviral treatments are available, many patients seek care after symptoms have already progressed, highlighting the need for new treatment options that may remain effective later in the course of infection.
Unlike conventional antivirals that directly inhibit viral replication, our lead molecule EV25 is designed to bind to infected cells and virions and recruit existing circulating antibodies, triggering rapid and targeted natural antibody immune clearance.
This antibody-recruiting mechanism works independently of viral replications, creating the potential for EV25 to treat both early and late-stage infections.
Eradivir has assembled a team of seasoned industry leaders, world class scientists and expert advisors.
